SV Health Investors

SV operates three dedicated verticals, each with its own investment team and fund structures. The Therapeutics group manages early- to late-stage biotech funds — including a Dementia Discovery Fund — while the Healthcare Growth team provides growth capital and liquidity to services, medical products, and digital health companies. The Medtech Convergence Fund focuses on novel medical devices and remote-monitoring technologies.

The firm invests across the full company lifecycle. Its strategies span seed, start-up, expansion, growth equity, management buyout, PIPE, and recapitalization. The Therapeutics unit funds precision medicine from early discovery through late-stage development, while the Growth Fund typically enters at the expansion stage and beyond.

SV invests primarily in the United States and Europe, with offices in Boston and London. Its portfolio and exited investments reflect a transatlantic footprint — companies such as AeroCare Holdings and Insulet originated in the US, while firms like Convergence Pharmaceuticals and Solexa Ltd were based in Europe.

Managing Partners Kate Bingham and Laurence Barker co-lead the Therapeutics team, Michael Balmuth and Tom Flynn head Healthcare Growth, and Paul LaViolette and Greg Madden oversee Medtech and Healthcare Growth. Senior Partners such as Mike Ross and Eugene Hill also shape strategy across the platform.

Yes. SV runs a standalone Dementia Discovery Fund (DDF) within its Therapeutics vertical. The DDF has its own Scientific Advisory Board of experts, including Maria Carrillo, Chief Science Officer of the Alzheimer's Association, and operates alongside the firm's broader biotech funds.

The firm reports 75 IPOs and M&A exits over its history. Disclosed realized investments include Alector, Insulet, Ophthotech (now Iveric bio), Shire Pharmaceuticals, and Solexa Ltd — spanning biotech, medical devices, and specialty pharmaceuticals.

SV manages dedicated funds across its three verticals and invests directly into companies. It does not market itself as a fund-of-funds, but its Growth Fund Advisory Board and operating-partner network suggest capital is deployed alongside co-investors directly into healthcare operating companies.